Parra Sánchez, Agner R.
Voskuyl, Alexandre E.
van Vollenhoven, Ronald F. http://orcid.org/0000-0001-6438-8663
Article History
Accepted: 14 December 2021
First Online: 17 January 2022
Change Date: 11 February 2022
Change Type: Update
Change Details: The formatting of Agner R. Parra Sánchez’s name in the xml was incorrect, resulting in Parra being wrongly classed as a middle name. This has now been corrected online.
Competing interests
: R.F.v.V. declares that he has received research support (institutional grants) from BMS, GSK, Lilly and UCB and support for educational programmes from Pfizer and Roche. R.F.v.V. declares that he has also received consulting fees from AbbVie, AstraZeneca, Biogen, Biotest, BMS, Galapagos, Gilead, Janssen, Pfizer, Sanofi, Servier, UCB and Vielabio and personal honoraria as a speaker from AbbVie, Galapagos, GSK, Janssen, Pfizer and UCB. A.E.V. declares that he has received research support (institutional grants) from GSK and UCB, consulting fees from GSK, AstraZeneca and Roche, and personal honoraria as a speaker from GSK. A.R.P.S. declares no competing interests.